

Confirmed ORR by UpRi Dose Group and NaPi2b Level, Duration of Response

44% ORR in Dose Group 36 for Patients With NaPi2b-High Ovarian Cancer

		All Dose Levels	Dose Group 36	Dose Group 43
NaPi2b-High (TPS ≥75)	N	38	16	22
	ORR, n (%)	13 (34)	7 (44)	6 (27)
	CR, n (%)	2 (5)	2 (13)	0
	PR, n (%)	11 (29)	5 (31)	6 (27)
	DCR, n (%)	33 (87)	12 (75)	21 (95)
All NaPi2b Levels	N	75	25	48
	ORR, n (%)	17 (23)	9 (36)	8 (17)
	CR, n (%)	2 (3)	2 (8)	0
	PR, n (%)	15 (20)	7 (28)	8 (17)
	DCR, n (%)	54 (72)	18 (72)	35 (73)

- Median DoR in patients (all dose levels) with NaPi2b-high ovarian cancer (n=13): 5 months
- No obvious difference in median DoR observed between Dose Groups 36 and 43

Data cut: June 10, 2021. Two patients received <30 mg/m² and therefore were not included in either dose group. All responses are confirmed. There were 75 evaluable patients. There were 22 unevaluable patients: 4 in Dose Group 36, 2 patient withdrawals (1 enrolled in hospice), 2 patient deaths; 18 in Dose Group 43, 5 patient withdrawals, 1 clinical progression, 3 due to adverse events, 8 deaths, 1 had not reached first scan. Of 4 unevaluable patients in Dose Group 36, 2 were NaPi2b-high; of 18 unevaluable in Dose Group 43, 10 were NaPi2b-high.

CR, complete response; DCR, disease control rate; DoR, duration of response; NaPi2b, sodium-dependent phosphate transport protein 2B; ORR, overall response rate; PR, partial response; TPS, tumor proportion score; UpRi, upifitamab rilsodotin.